ENDRA Life Sciences Inc.
NDRA
$5.50
-$0.42-7.10%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.46M | 6.23M | 6.83M | 7.63M | 4.85M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.44M | 8.58M | 9.51M | 10.82M | 7.98M |
| Operating Income | -8.44M | -8.58M | -9.51M | -10.82M | -7.98M |
| Income Before Tax | -8.01M | -8.77M | -9.77M | -11.51M | -8.82M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.01 | -8.77 | -9.77 | -11.51 | -8.82 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.01M | -8.77M | -9.77M | -11.51M | -8.82M |
| EBIT | -8.44M | -8.58M | -9.51M | -10.82M | -7.98M |
| EBITDA | -8.39M | -8.53M | -9.46M | -10.77M | -7.92M |
| EPS Basic | -13.35 | -20.79 | -162.07 | -160.21 | -152.52 |
| Normalized Basic EPS | -8.35 | -13.00 | -101.29 | -100.13 | -95.33 |
| EPS Diluted | -13.35 | -20.79 | -162.07 | -160.21 | -152.52 |
| Normalized Diluted EPS | -8.35 | -13.00 | -101.29 | -100.13 | -95.33 |
| Average Basic Shares Outstanding | 2.58M | 2.06M | 1.36M | 802.00K | 262.40K |
| Average Diluted Shares Outstanding | 2.58M | 2.06M | 1.36M | 802.00K | 262.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |